Articles tagged "Antibodies"

2015 American Transplant Congress
Are AT1R Antibodies as Dangerous as HLA-DSAs in Renal Allografts?
E. Cuevas, J. Arreola-Guerra, E. Hernandez-Mendez, I. Salcedo, M. Vilatoba, A. Contreras, A. Sanchez-Cedillo, J. Ramirez, D. de Rungs, J. Granados, L. Morales-Buenrostro, J. Alberu.
1Transplantation, 1aNephrology-Mineral Metabolism, Inst Nal de Ciencias Medicas y Nutricion SZ, Mexico City, Distrito Federal, Mexico.
Angiotensin II type 1 receptor antibodies (AT1Rab) have been associated with a significantly lower graft survival and a higher risk of acute rejection after kidney…
2015 American Transplant Congress
DSA Monitoring in Kidney Transplant Recipients
F. Pean,¹ M. Cooper,¹ J. Verbesey,¹ A. Gilbert,¹ B. Javaid,¹ R. Mohammed,¹ O. Timofeeva,² J. Moore,¹ K. Cruz,¹ R. Ghasemian,¹ T. Fishbein,¹ M. Grafals.¹
¹Medstar Georgetown Transplant Institute, Georgetown University, Washington, DC; ²Clinical Laboratory and Histocompatibility, Georgetown University, Washington, DC.
Introduction: The development of DSA monitoring is a new technique to detect antibodies in kidney transplant recipients. Data has shown that development of DSA post…
2015 American Transplant Congress
Mesenchymal Stem Cells (MSCs) Transfusion for Desensitization of Positive Lymphocyte Cross Match (LCM) or Panel Reactive Antibodies (PRA) Before Kidney Transplantation – Outcome of 16 Cases
G. Saadi,¹ K. Eweda,² M. Hassaballa,¹ F. Fadel,³ E. Aziz,² M. Roshdi,¹ M. El Ansary,⁴ I. Aziz,⁴ W. Ismail,⁵ A. Atef,¹ S. Hamid.⁴
¹Internal Medicine and Nephrology, Cairo University, Cairo, Egypt; ²Nephrology, Army Hospital, Cairo, Egypt; ³Pediatric Nephrology, Cairo University, Cairo, Egypt; ⁴Clinical Pathology, Cairo University, Cairo, Egypt; ⁵Pathology, Beni Sweif University, Beni Sweif City, Egypt.
Immunomodulatory function of MSCs may correct positive PRA or LCM in highly-sensitized patients. We evaluate donor specific or 3rd party MSCs transfusion in 16 patients…
2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
R. Bray,¹ H. Gebel,¹ R. Townsend,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta; ²Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…
2015 American Transplant Congress
Changes in Donor Specific Antibodies (DSA) First Year After Kidney Transplant (KTX): Implications for Graft Histology and Survival
F. Cosio,¹ C. Schinstock,¹ L. Cornell,³ F. de Teresa,¹ M. Stegall.²
¹Nephrology, Mayo Clinic, Rochester, MN; ²Surgery, Mayo Clinic, Rochester, MN; ³Pathology, Mayo Clinic, Rochester, MN.
Introduction. De novo DSA post-KTx is associated with high risk of chronic antibody mediated rejection (cAMR) and reduced graft survival. DSA changes during first year…
2015 American Transplant Congress
Eculizumab as a Rescue Therapy for Rhinovirus-Induced Antibody Mediated Rejection After Incompatible Kidney Transplantation
E. Tantisattamo, A. Shetty, B. Ho, L. Gallon, J. Friedewald.
Northwestern University, Chicago, IL.
Background: Despite being an effective strategy for overcoming ABO and HLA incompatibilities, desensitized kidney transplantation still has limitations. Early antibody mediated rejection (ABMR) may be…
2015 American Transplant Congress
The Use of Bortezomib for Desensitization in ABO Incompatible and Positive Crossmatch Kidney Transplant
J. Benken,¹ S. Akkina,² E. Benedetti.³
¹Pharmacy Practice, Univ. of IL-Chicago, Chicago, IL; ²Dept. of Medicine, Nephrology, Univ. of IL-Chicago, Chicago, IL; ³Dept. of Surgery, Univ. of IL-Chicago, Chicago, IL.
Introduction:ABO incompatible (ABOi) and positive crossmatch (PXM) living donor kidney transplantation is a life-saving alternative to dialysis. A variety of protocols exist utilizing plasmapheresis (PP)…
2015 American Transplant Congress
LFA-1 Is Crucial for Germinal Center Reconstruction After T cell Depletion and IL-21 Biased Antibody-Mediated Rejection
J. Kwun,¹ B. Oh,¹ H. Song,¹ A. Farris,¹ A. Kirk,² W. Mahle,¹ S. Knechtle.¹
¹Surgery, Emory Transplant Center, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
[Background] Lymphocyte depletion prior to transplantation is beneficial in reducing initial maintenance immunosuppression in transplantation. However, despite its excellent efficacy in controlling T cell mediated…
2015 American Transplant Congress
Improving ABMR Diagnostics Through Advanced Anti-HLA Antibody Screening Techniques
R. Ponsirenas,^1,2 H. Cazarote,^1,2 S. Shimakura,³ J. Valdameri,¹ F. Contieri,⁴ C. von Glehn,^1,2 M. Susin.^1,2
¹Transplant Immunology Laboratory, Pontifícia Universidade Católica do Paraná, Curitiba, Parana, Brazil; ²Medicine School, Pontifícia Universidade Católica do Paraná, Curitiba, Parana, Brazil; ³Departament of Statistics, Universidade Federal do Parana, Curitiba, Parana, Brazil; ⁴Kidney Transplant Unit, Hospital Evangélico de Curitiba, Curitiba, Parana, Brazil.
The identification of low-level antibodies by single antigen bead methodology has brought advancements in risk evaluation of kidney transplants recipients. However, the use of the…
2015 American Transplant Congress
Microvascular (MIA) and Interstitial (i) Inflammation Influence Late Death-Censored Graft Failure (DCGF) After Kidney Transplantation
R. Gaston,¹ A. Fieberg,² R. Leduc,² J. Connett,² F. Cosio,³ S. Gourishankar,⁴ J. Grande,³ L. Hunsicker,⁵ B. Kasiske,⁶ J. Cecka,⁷ A. Matas,² D. Rush.⁸
¹UAB, Birmingham; ²U Minnesota, Minneapolis; ³Mayo Clinic, Rochester; ⁴U Alberta, Edmonton, Canada; ⁵U Iowa, Iowa City; ⁶Hennepin County Med Ctr, Minneapolis; ⁷UCLA Immunogenetics, Los Angeles; ⁸U Manitoba, Winnipeg, Canada.
We and others have shown late DCGF is due to ongoing, most often immune, injury. Though there is general agreement that antibody-mediated injury is a…